Enzyme
Merus’ Petosemtamab Demonstrates Promising Efficacy in Head and Neck Cancer, Enhancing Its ‘Best-in-Disease’ Profile
Petosemtamab, Head and Neck Cancer, Clinical Trials, Merus, ESMO Asia Congress 2024, Biclonics, EGFR and LGR5
Daiichi Sankyo and Alteogen Collaborate on Subcutaneous Enhertu Development in $300M Licensing Agreement
Daiichi Sankyo, Alteogen, subcutaneous Enhertu, $300M licensing deal, human hyaluronidase, cancer treatment
Tyra Biosciences Unveils Early Data for FGFR3 Inhibitor, TYRA-300, in Challenge to J&J’s Balversa
Tyra Biosciences, TYRA-300, Balversa, J&J, bladder cancer, urothelial carcinoma, FGFR3 inhibitor, safety concerns, efficacy data
Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases
Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration
Black Diamond Therapeutics Refocuses on Lung Cancer Drug BDTX-1535 Amid Workforce Reduction
Black Diamond Therapeutics, workforce reduction, lung cancer drug, BDTX-1535, EGFR mutations, Tagrisso, tyrosine kinase inhibitor
Roche Invests $850 Million in Regor’s Next-Generation CDK Inhibitors for Breast Cancer Treatment
Roche, Regor Pharmaceuticals, CDK inhibitors, breast cancer, Genentech, pharmaceutical acquisition
Roche Acquires Regor’s CDK Inhibitors for $850M to Enhance Breast Cancer Portfolio
Roche, Regor Therapeutics, CDK inhibitors, breast cancer, Genentech, pharmaceutical acquisition, transformative medicines
FDA Approves Rybrevant for Third NSCLC Indication This Year
Rybrevant, NSCLC, FDA approval, J&J, EGFR mutations, lung cancer treatment
J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen
Sun Pharma Secures FDA Approval for Leqselvi, a JAK Inhibitor for Severe Alopecia Areata
Sun Pharma, Leqselvi, FDA Approval, Alopecia Areata, JAK Inhibitor, Pfizer, Lilly, Immunology, Dermatology